Equities Analysts Offer Predictions for KTTA FY2026 Earnings

Pasithea Therapeutics Corp. (NASDAQ:KTTA) – Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for Pasithea Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Nik now expects that the company will post earnings of ($1.86) per share for the year, down from their prior forecast of ($0.68). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($2.30) EPS.

KTTA has been the subject of several other reports. Zacks Research raised Pasithea Therapeutics to a “hold” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, January 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Pasithea Therapeutics Stock Performance

NASDAQ KTTA opened at $0.77 on Friday. The business’s 50 day moving average is $0.79 and its two-hundred day moving average is $0.85. Pasithea Therapeutics has a 12-month low of $0.28 and a 12-month high of $3.79. The stock has a market capitalization of $19.20 million, a price-to-earnings ratio of -0.22 and a beta of 0.25.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.71).

Institutional Investors Weigh In On Pasithea Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC purchased a new stake in shares of Pasithea Therapeutics during the 4th quarter worth approximately $2,720,000. Vivo Capital LLC purchased a new position in Pasithea Therapeutics in the 4th quarter valued at approximately $2,709,000. Squadron Capital Management LLC purchased a new position in Pasithea Therapeutics in the 4th quarter valued at approximately $2,709,000. Adage Capital Partners GP L.L.C. acquired a new position in Pasithea Therapeutics during the fourth quarter worth $2,709,000. Finally, AdvisorShares Investments LLC raised its holdings in Pasithea Therapeutics by 18.2% during the fourth quarter. AdvisorShares Investments LLC now owns 304,721 shares of the company’s stock worth $393,000 after purchasing an additional 47,025 shares during the last quarter. 23.92% of the stock is currently owned by institutional investors and hedge funds.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.